Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502890 · ClinicalTrials.gov registry record
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
A clinical trial of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 208
- Enrollment target
- 9
- Study locations
NCT02502890 is a study of Asthma that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 208 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT02502890, a study of Asthma, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 208 participants
- Enrollment target
- 9
- Study locations
Study Summary
Asthma is a growing problem, especially in children. It causes frequent wheezing, shortness of breath, chest tightness, and cough. A cold that is caused by a virus (viral cold) can sometimes make asthma symptoms worse. This study will help investigators learn about the way colds are related to asthma attacks among children who need higher amounts of medications to control their asthma. Investigators want to learn why viral colds sometimes cause asthma attacks and other times do not by studying the immune system response in samples taken from the nose and blood.
Conditions Studied
Study Locations (9)
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Ann and Robert Lurie Children's Hospital of Chicago - Chicago
Massachusetts
- Boston University School of Medicine - Boston
Michigan
- Henry Ford Health System - Detroit
Missouri
- St. Louis Children's Hospital - St Louis
New York
- Columbia University Medical Center - New York
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02502890
The ClinicalTrials.gov registry entry for NCT02502890 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 0 interventions.
NCT02502890 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Colorado, District of Columbia, Illinois.
Frequently Asked Questions
What is clinical trial NCT02502890 about?
NCT02502890 is a clinical study titled "Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy". Asthma is a growing problem, especially in children. It causes frequent wheezing, shortness of breath, chest tightness, and cough. A cold that is caused by a virus (viral cold) can sometimes make asthma symptoms worse. This study will help investigators learn about the way colds are related to asthm...
What is the current status of trial NCT02502890?
This trial is currently completed. The enrollment target is 208 participants. The study started on 2015-10. Estimated completion is 2017-01.
What conditions does trial NCT02502890 study?
This clinical trial studies the following conditions: Asthma.
Who is sponsoring clinical trial NCT02502890?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02502890 being conducted?
This trial has 9 study locations across Colorado, District of Columbia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.